Bonsall, David
Perceptive, London, United Kingdom
3 papers on CoChatORCID 0000-0002-2542-7559
Most cited papers
- Verified
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats
Onwordi, E. C., Halff, E. F., Whitehurst, T., Mansur, A., Cotel, M.-C., Wells, L., Creeney, H., Bonsall, D., Rogdaki, M., Shatalina, E., et al. (2020) · Nature Communications
Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior
Cited by 243
- Verified
Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery
Bernard-Gauthier, V., Mossine, A. V., Knight, A., Patnaik, D., Zhao, W.-N., Cheng, C., Krishnan, H. S., Xuan, L. L., Chindavong, P. S., Reis, S. A., et al. (2019) · Journal of Medicinal Chemistry
Alzheimer's disease research and treatmentsWnt/β-catenin signaling in development and cancer
Cited by 49
- Verified
Evaluation of [ 3 H]SynVesT‐1 binding parameters in post‐mortem brain tissue from control and Alzheimer's Disease
Lemoine, L., Kulagowska, L., Bonsall, D., King, D., Gladstein, S., Bevis, A., Sabandal, M., Wells, L., Finnema, S. J., Spires‐Jones, T. L., et al. (2025) · Alzheimer's & Dementia
Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research
Cited by 1
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free